EPIQ Capital Group

Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body. The company's therapeutics are used to create next-generation programmable nucleases that can selectively target and edit cells, enabling physicians to treat their patient in an enhanced way.

Epirus develops solid-state, software-defined directed energy systems for counter-electronics applications and power management in defense and commercial sectors. The company specializes in long-pulse high-power microwaves combined with AI and advanced electronics for electronic warfare.

SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.

VideoAmp is a software and data company creating a data-driven advertising ecosystem that redefines how media is valued, bought, and sold. Its platform unifies audiences across traditional TV, streaming video, and digital media with the ability to connect media exposures to an advertiser’s sales. By unlocking new value for the entire landscape, its platform allows advertisers, agencies, and media sellers to align on VideoAmp’s independent measurement as a multi-platform media currency to transact against.

Founded in 2016, Windfall Data is on a mission to determine the net worth of everyone on the planet. The company serves nonprofit and for-profit organizations by providing actionable consumer financial data that is refreshed on a weekly basis. More than 400 organizations use Windfall Data to identify and engage their most promising constituents. Windfall Data is based in San Francisco and backed by Bullpen Capital, Bonfire Ventures, Industry Ventures, TenOneTen Ventures, ValueStream Ventures, and Auren Hoffman.

Swift Navigation is a technology company that provides precise positioning solutions for automotive advanced driver-assistance systems. The company was founded in 2012 to make GPS positioning technology more accurate and affordable. Today Swift Navigation has gained a reputation for defining a new category of GNSS systems as the industry’s first low-cost, high-accuracy real-time kinematics (RTK) receiver. Its GPS and GNSS positioning products are available at a fraction of the price of the competition and deliver 100 times better accuracy than the GPS in a cell phone. Swift Navigation’s technology benefits a multitude of industries and applications—including autonomous vehicles, unmanned aerial vehicles (UAVs), precision agriculture, robotics, surveying, and space. With its innovation and technology honored by Inc.’s and Forbes 30 Under 30 lists, Swift Navigation is enabling a world where fields farm themselves, drones fly safely and autonomous transportation can take you home. Swift Navigation provides an end-to-end GNSS solution with a line of Piksi, Multi, and Duro / Duro Inertial receivers, Starling, Positioning Engine, and Skylark Cloud Corrections Service.

Lineage Logistics is an innovator in temperature-controlled supply chain and logistics. Lineage’s expertise in end-to-end logistical solutions, its unrivaled real estate network, and its use of technology combine to promote food safety, increase distribution efficiency, advance sustainability, lessen environmental impact, and minimize supply chain waste. As a result, Lineage helps customers ranging from Fortune 500 companies to small family-owned businesses increase the efficiency and protect the integrity of their temperature-controlled supply chain. In recognition of the company’s leading innovations, Lineage was recognized as the No 1. Data Science company on Fast Company’s annual list of the World’s Most Innovative Companies in 2019, in addition to ranking 23rd overall in an evaluation of thousands of companies worldwide.

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.

SpotOn’s mission is to give small and midsize businesses a fighting chance, providing innovative software and payment solutions, supported by local and personal service, and delivered at a fair price. A leader in fully integrated restaurant management systems and small business technology, SpotOn offers end-to-end solutions which include marketing, website development, reservations, online ordering, appointments, eCommerce, digital loyalty, review management, as well as retail and restaurant point-of-sale (POS) solutions. Doron Friedman, Matt Hyman, and Zach Hyman co-founded SpotOn in 2017 and its headquarters is located in San Francisco, California.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing oral biologic product candidates in patient-friendly tablet and capsule forms that are designed for either targeting local gastrointestinal (GI) tissue or entering systemic circulation to precisely address the relevant biology of a disease. AMT is building a portfolio of oral product candidates based on its technology platform including its lead product candidate, AMT-101, an oral GI-selective interleukin 10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). AMT further plans to initiate Phase 2 clinical trials of AMT-101 in UC and related inflammatory indications. AMT’s technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and RNA therapeutics, with potentially significant advantages over existing marketed and development-stage drugs.

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.

Swift Navigation is a technology company that provides precise positioning solutions for automotive advanced driver-assistance systems. The company was founded in 2012 to make GPS positioning technology more accurate and affordable. Today Swift Navigation has gained a reputation for defining a new category of GNSS systems as the industry’s first low-cost, high-accuracy real-time kinematics (RTK) receiver. Its GPS and GNSS positioning products are available at a fraction of the price of the competition and deliver 100 times better accuracy than the GPS in a cell phone. Swift Navigation’s technology benefits a multitude of industries and applications—including autonomous vehicles, unmanned aerial vehicles (UAVs), precision agriculture, robotics, surveying, and space. With its innovation and technology honored by Inc.’s and Forbes 30 Under 30 lists, Swift Navigation is enabling a world where fields farm themselves, drones fly safely and autonomous transportation can take you home. Swift Navigation provides an end-to-end GNSS solution with a line of Piksi, Multi, and Duro / Duro Inertial receivers, Starling, Positioning Engine, and Skylark Cloud Corrections Service.

Tenstorrent designs and manufactures AI hardware and software for data processing and machine learning tasks. It provides solutions for computational performance. Its products are used in various applications within the technology sector. Tenstorrent serves developers and researchers in the field of artificial intelligence.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing oral biologic product candidates in patient-friendly tablet and capsule forms that are designed for either targeting local gastrointestinal (GI) tissue or entering systemic circulation to precisely address the relevant biology of a disease. AMT is building a portfolio of oral product candidates based on its technology platform including its lead product candidate, AMT-101, an oral GI-selective interleukin 10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). AMT further plans to initiate Phase 2 clinical trials of AMT-101 in UC and related inflammatory indications. AMT’s technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and RNA therapeutics, with potentially significant advantages over existing marketed and development-stage drugs.

Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.